Olusola Olusesan Faluyi

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

Richard Fox, Daniel H. Palmer, Hassan Malik et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson et al. · JAMA Surgery · 2019 · 273 citations · Full text

Medicine, Oncology, Surgery +13

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

Daniel H. Palmer, Juan W. Valle, Yuk Ting et al. · British Journal of Cancer · 2020 · 67 citations · Full text

Medicine, Immunology, Oncology +17

Breast Radiotherapy for Occult Breast Cancer with Axillary Nodal Metastases — Does it Reduce the Local Recurrence Rate and Increase Overall Survival?

S. Masinghe, Olusola Olusesan Faluyi, G.R. Kerr et al. · Clinical Oncology · 2010 · 44 citations

Medicine, Oncology, Radiation Oncology +17